Covington Represents ClearPoint Neuro on Investment of up to $110 Million by Oberland Capital

NEW YORK–Covington advised ClearPoint Neuro, Inc. in its entrance into a note financing arrangement with Oberland Capital Management LLC of up to $110 Million, with $33.5 million of gross proceeds funded at closing.

ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. ClearPoint Neuro uniquely provides both established clinical products as well as preclinical development services for controlled drug and device delivery. Its flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America.

Oberland Capital is a private investment firm formed in 2013 with assets under management in excess of $3.0 billion, focused exclusively on investing in the global healthcare industry and specializing in flexible investment structures customized to meet the specific needs of its transaction partners.